Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXL770 tablet versus capsule relative bioavailability and food-effect crossover study
NL-OMON49206Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PXL770 in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (6 arms), sponsored by Poxel SA. Primary endpoint: Relative bioavailability and primary pharmacokinetic comparison. Started Sep 2020; status: completed.
02
Drugs
PXL770
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON49206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49206.